Abbott Laboratories (ABT) said Thursday it has launched a clinical trial aimed at evaluating the impact of earlier intervention using its HeartMate 3 left ventricular assist device, or heart pump, in patients with advanced heart failure.
The study, targeted to enroll up to 850 patients at 75 global sites, will use Abbott's CardioMEMS HF System sensor to monitor pulmonary artery pressures and identify patients who may benefit from early intervention with the HeartMate 3 heart pump, according to Abbott.
Abbott said enrollment will start shortly in the US. The study will assess primary and secondary endpoints after two years and continue monitoring participants for up to five years, the company added.
Price: 116.66, Change: -0.35, Percent Change: -0.30
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。